Torem (torsemide), the originator brand marketed in the UK and parts of Europe, is a loop diuretic licensed for oedema in heart failure, renal and hepatic disease and for hypertension; the US originator brand Demadex has been discontinued, so FDA-approved generic torsemide tablets now supply that market, alongside MHRA-licensed generic torasemide in the UK.
M Care Exports supplies Torem (torsemide), a pyridine-sulfonylurea loop diuretic marketed in the UK and parts of Europe, alongside FDA-approved generic torsemide tablets for markets where the US originator brand Demadex has been discontinued, and MHRA-licensed generic torasemide in the UK. It is dosed once daily for oedema and hypertension, with more consistent oral absorption than furosemide. M Care is a merchant exporter: we source Torem and generic torsemide through licensed Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Torsemide exporter and bulk supplier from India.
For hospital, wholesaler and tender-desk orders, M Care quotes torsemide tablets against buyer specification: brand (Torem, where registered) or generic, strength mix (5 mg, 10 mg, 20 mg, 100 mg) and destination-market regulatory documentation, drawn from licensed WHO-GMP manufacturer lines on the M Care roster. Because torsemide's heart-failure dosing is titrated by doubling from a 10-20 mg starting dose while hypertension is dosed at a fixed 5-10 mg, we confirm the buyer's intended indication mix before dispatch, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Loop diuretic (pyridine-sulfonylurea class); Na+/K+/2Cl- co-transporter inhibitor, sourced and documented for export.
Torsemide is a pyridine-sulfonylurea loop diuretic that inhibits the Na+/K+/2Cl- co-transporter in the thick ascending limb of the loop of Henle, increasing excretion of sodium, chloride and water. Unlike furosemide, its oral bioavailability is consistently high, around 80%, and is largely unaffected by gut-wall oedema in decompensated heart failure, which gives more predictable diuresis and supports once-daily dosing. The FDA label's flagship indications are oedema associated with heart failure, renal disease or hepatic disease, and hypertension alone or with other antihypertensive agents; the UK SmPC for Torem covers oedema due to congestive heart failure and hepatic, pulmonary or renal oedema. It is an oral-only therapy in the markets we ship to, needing no reconstitution. Torsemide is supplied as 5 mg, 10 mg, 20 mg and 100 mg tablets, the strength set matching the original Demadex/Torem line and licensed generics.
Active ingredient
Torsemide. Loop diuretic (pyridine-sulfonylurea class); Na+/K+/2Cl- co-transporter inhibitor.
Forms and strengths
5 mg tablet; 10 mg tablet; 20 mg tablet; 100 mg tablet.
Indications
Torsemide, a pyridine-sulfonylurea loop diuretic indicated for oedema associated with heart failure, renal or hepatic disease, and for hypertension. Supplied as originator Torem and FDA/MHRA-licensed generic torsemide tablets, the US originator brand Demadex being discontinued, from Indian WHO-GMP facilities to regulated and semi-regulated markets outside India.
Administration
Oral. Tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for torsemide are hospital cardiology and heart-failure pharmacies managing chronic oedema, nephrology and hepatology units treating renal or hepatic oedema, national and regional MoH tender desks running cardiovascular and NCD formulary lists, licensed pharmaceutical wholesalers and importers, and retail pharmacy chains across our GCC and African markets stocking an oral loop diuretic alongside furosemide where local scheduling permits.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on torsemide.
Torsemide dosing is indication-specific: heart failure starts at 10-20 mg once daily, titrated by doubling until the diuretic response is adequate; chronic renal failure starts at 20 mg with the same doubling approach; hepatic cirrhosis starts low, at 5-10 mg alongside an aldosterone antagonist; and hypertension is dosed at a fixed 5 mg, rising to 10 mg only if control is inadequate after four to six weeks, so pack-mix planning should reflect the tender's stated indication. Torsemide is contraindicated in anuria and in patients with known hypersensitivity to sulfonylureas, so a documented sulfonamide or sulfonylurea allergy should stop dispensing at the counter. In renal impairment, renal clearance of torsemide falls but total plasma clearance stays close to normal because hepatic metabolism is a major elimination route, so higher doses rather than shorter dosing intervals restore diuretic response. UK labelling states torasemide should not be used in pregnancy unless the clinical condition of the woman requires it, and that a risk to the breastfed infant cannot be excluded. No reconstitution and no cold chain are required; tablets store at controlled room temperature.
The documentation pack a regulator actually asks for.
As an oral solid dosage form, torsemide travels on standard ambient-temperature logistics rather than the validated cold-chain lanes M Care runs for biologics and insulins. What buyers need instead is batch-level certificate of analysis, CDSCO export documentation and, where the destination market requires it, CTD or eCTD-format dossier support so the buyer's own regulator can register the product; UK Torem tablets carry a four-year shelf life with no special storage precautions, per the current SmPC. Torsemide does not appear by name on the WHO Model List of Essential Medicines; the WHO electronic EML lists furosemide as the reference loop diuretic and records torasemide as a therapeutic equivalent for heart failure, oedema and anuria or oliguria, so buyers should treat torsemide as a formulary-specific alternative to furosemide rather than an EML first-line agent when building a tender specification. On the brand-versus-generic question, Demadex was the FDA-approved US originator, first approved under NDA 020136 in 1993, but all strengths are now discontinued in the US; Torem remains an actively marketed originator brand in the UK and parts of Europe. FDA-approved generic torsemide tablets from multiple manufacturers now supply the US market, and MHRA-licensed generic torasemide is available in the UK alongside Torem, so buyers have a genuine brand-or-generic choice outside the US and a generic-only choice within it. Torsemide is not a controlled substance in the markets we currently review.
The paperwork above is the molecule-specific part; the general pathway a destination regulator expects is set out in our licensed import route guide.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside torsemide.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for torsemide.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Torsemide supply, the specific questions.
Does a generic version of Demadex or Torem exist?
Yes. The Demadex brand itself is no longer marketed in the US, where FDA-approved generic torsemide tablets from multiple manufacturers now supply the market. In the UK, MHRA-licensed generic torasemide is available alongside the still-marketed Torem brand. Registration status varies by destination country, so M Care checks local approval before quoting brand or generic against a specific tender.
Can M Care supply Torem or generic torsemide to our market?
Yes, on an import basis. Torem remains an actively marketed originator brand in the UK and parts of Europe; the US originator brand Demadex has been discontinued, so US-market sourcing is generic torsemide only. We source through licensed Indian distribution channels and dispatch against your import authorisation and any local registration your pharmacy, hospital or wholesaler holds.
What strengths of torsemide tablets are available?
5 mg, 10 mg, 20 mg and 100 mg tablets, the strength set approved for the original Demadex/Torem line and matched by licensed generics. Tell us your indication mix, heart failure, renal or hepatic oedema, or hypertension, and we quote the strength split accordingly.
Is torsemide on the WHO Essential Medicines List?
Not by name. Furosemide is the loop diuretic WHO lists as an essential medicine; the WHO electronic EML records torasemide separately as a therapeutic equivalent to furosemide for heart failure, oedema and anuria or oliguria. Torsemide has higher and more consistent oral bioavailability than furosemide, around 80%, because absorption is less affected by gut-wall oedema in decompensated heart failure, and its longer half-life supports once-daily dosing. Tender desks typically specify torsemide as a formulary-specific alternative rather than an EML first-line diuretic.
Is torsemide safe in pregnancy or breastfeeding?
Data are limited. UK labelling for Torem states that torasemide should not be used in pregnancy unless the clinical condition of the woman requires treatment with it, and that a risk to a breastfed infant cannot be excluded, so the prescriber should weigh therapeutic benefit against continued breastfeeding. This should be reflected in destination-market patient information leaflets.
What documentation does M Care provide with a torsemide shipment?
Batch-level certificate of analysis, CDSCO export documentation from the Indian side, and CTD/eCTD-aligned dossier support where the destination regulator requires local registration before import, along with confirmation of which brand or generic product a shipment contains.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-14.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.